Sleep therapy system receives $58.5M in funding

Tuesday, December 19, 2017

MINNETONKA, Minn. – The makers of a transvenous implantable neurostimulation system for treating central sleep apnea have received $58.5 million in financing. The financing for Respicardia and its remedē System was led by ZOLL Medical Corp., a manufacturer of medical devices and related software solutions. "We believe the remedē System will soon become the treatment of choice for patients suffering from central sleep apnea," stated Bonnie Labosky, president and CEO of Respicardia. "Proceeds from the financing will be used to fund our U.S. commercialization efforts and support ongoing development of the system." The system received approval from the U.S. Food and Drug Administration in October 2017, paving the way for its market release in the United States. The system stimulates the phrenic nerve and engages the diaphragm to restore a normal breathing pattern during sleep. A trial published in Lancet show the system can significantly reduce the severity of central sleep apnea, and improve sleep, quality of life and patient satisfaction.